Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3829-3838

  Tokuhara, Daisuke ^a,b   Álvarez, Beatriz ^c   Mejima, Mio ^a   Hiroiwa, Tomoko ^a   Takahashi, Yuko ^a   Kurokawa, Shiho ^a   Kuroda, Masaharu ^d   Oyama, Masaaki ^a   Kozuka Hata, Hiroko ^a   Nochi, Tomonori ^a   Sagara, Hiroshi ^a   Aladin, Farah ^e   Marcotte, Harold ^c   Frenken, Leon G J ^f   Iturriza Gómara, Miren ^g   Kiyono, Hiroshi ^a   Hammarström, Lennart ^c   Yuki, Yoshikazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NATIONAL AGRICULTURAL RESEARCH CENTER   (Japan)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARP1 ANTIBODY; POLYCLONAL ANTIBODY; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG PURIFICATION; GENE EXPRESSION SYSTEM; HEAT TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PLANT SEED; PRIORITY JOURNAL; RICE; ROTAVIRUS INFECTION; STORAGE; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; ANTIBIOTIC PROPHYLAXIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROTEIN STABILITY; ROTAVIRUS; ROTAVIRUS INFECTIONS; SCID MOUSE; SMALL INTESTINE; SOLUBILITY; TRANSGENIC PLANT; VIROLOGY; VIRUS SHEDDING;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DIARRHEA; HUMANS; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; MICE, SCID; ORYZA SATIVA; PLANTS, GENETICALLY MODIFIED; PROTEIN STABILITY; ROTAVIRUS; ROTAVIRUS INFECTIONS; SEEDS; SINGLE-CHAIN ANTIBODIES; SOLUBILITY; VIRUS SHEDDING;

EID: 84883532793     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70266     Document Type: Article

References (65)

1. O'Ryan M, et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J. 2001;20(7):685-693. (Pubitemid 32652320)
2. Nakagomi T, Nakagomi O, Takahashi Y, Enoki M, Suzuki T, Kilgore PE. Incidence and burden of rotavirus gastroenteritis in Japan, as estimated from a prospective sentinel hospital study. J Infect Dis. 2005;192(suppl 1):S106-S110. (Pubitemid 41193110)
3. Fischer TK, et al. Hospitalizations and deaths from diarrhea and rotavirus among children < 5 years of age in the United States, 1993-2003. J Infect Dis. 2007;195(8):1117-1125. (Pubitemid 46543442)
4. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-572. (Pubitemid 36529515)
5. Bernstein DI. Rotavirus overview. Pediatric Infect Dis J. 2009;28(suppl 3):S50-S53.
6. Vesikari T, et al. Rotavirus efficacy and safety trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33. (Pubitemid 43048948)
7. Ruiz-Palacios GM, et al. Human rotavirus vaccine study group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22. (Pubitemid 43048947)
8. Glass RI, Parashar UD. The promise of new rotavirus vaccines. N Engl J Med. 2006;354(1):75-77. (Pubitemid 43048975)
9. Madhi SA, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362(4):289-298.
10. Armah GE, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606-614.
11. Zaman K, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615- 623.
12. Werther RL, Crawford NW, Boniface K, Kirkwood CD, Smart JM. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol. 2009;124(3):600.
13. Patel NC, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med. 2010;362(4):314-319.
14. Uygungil B, Bleesing JJ, Risma KA, McNeal MM, Rothenberg ME. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol. 2010;125(1):270-271.
15. Rotbart HA, et al. Neonatal rotavirus-associated necrotizing enterocolitis: case control study and prospective surveillance during an outbreak. J Pediatr. 1988;112(1):87-93. (Pubitemid 18054277)
16. Cunliffe NA, et al. Healthcare-associated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. Emerg Infect Dis. 2010;16(1):55-62.
17. Stelzmueller I, et al. A cluster of rotavirus enteritis in adult transplant recipients. Transpl Int. 2005;18(4):470-474. (Pubitemid 41726884)
18. Krüger W, Stockschläder M, Zander AR. Transmission of rotavirus diarrhea in a bone marrow transplantation unit by a hospital worker. Bone Marrow Transplant. 1991;8(6):507-508.
19. Gilger MA, Matson DO, Conner ME, Rosenblatt HM, Finegold MJ, Estes MK. Extraintestinal rotavirus infections in children with immunodeficiency. J Pediatr. 1992;120(6):912-917.
20. Oishi I, et al. Serial observations of chronic rotavirus infection in an immunodeficient child. Microbiol Immunol. 1991;35(11):953-961.
21. Liakopoulou E, et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2005;36(8):691-694. (Pubitemid 41518711)
22. Saulsbury FT, Winkelstein JA, Yolken RH. Chronic rotavirus infection in immunodeficiency. J Pediatr. 1980;97(1):61-65. (Pubitemid 10033764)
23. Sarker SA, et al. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr Infect Dis J. 1998;17(12):1149-1154. (Pubitemid 29023892)
24. Sarker SA, et al. Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 2001;32(1):19-25. (Pubitemid 32094491)
25. Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363(6428):446-448. (Pubitemid 23179389)
26. van der Linden RH, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta. 1999;1431(1):37-46.
27. Dolk E, et al. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins. 2005;59(3):555-564. (Pubitemid 40594299)
28. Frenken LG, et al. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. 2000;78(1):11-21. (Pubitemid 30084786)
29. van der Vaart JM, et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine. 2006;24(19):4130-4137. (Pubitemid 44308223)
30. Pant N, et al. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (Lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis. 2006;194(11):1580-1588. (Pubitemid 44851901)
31. Aladin F, et al. In vitro neutralization of rotavirus infection by two broadly specific recombinant monovalent llama-derived antibody fragments. PLoS One. 2012;7(3):e32949.
32. Nochi T, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci U S A. 2007;104(26):10986-10991. (Pubitemid 47175213)
33. Tokuhara D, et al. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A. 2010;107(19):8794-8799.
34. Yuki Y, et al. RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine. Vaccine. 2012;30(28):4160-4166.
35. Kuroda M, Kimizu M, Mikami C. A simple set of plasmids for the production of transgenic plants. Biosci Biotechnol Biochem. 2010;74(11):2348-2351.
36. Tanaka K, Sugimoto T, Ogawa M, Kasai Z. Isolation and characterization of two types of protein bodies in the rice endosperm. Agric Biol Chem. 1980;44(7):1633-1639.
37. Tanaka K, Hayashida S, Hongo M. The relationship of the feces protein particles to rice protein bodies. Agric Biol Chem. 1975;39(2):515-518.
38. Brüssow H, Hilpert H, Walther I, Sidoti J, Mietens C, Bachmann P. Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J Clin Microbiol. 1987;25(6):982-986. (Pubitemid 17079576)
39. Stoger E, et al. Practical considerations for pharmaceutical antibody production in different crop systems. Mol Breed. 2002;9(3):149-158. (Pubitemid 34973560)
40. Ismaili A, Jalali-Javaran M, Rasaee MJ, Rahbarizadeh F, Forouzandeh-Moghadam M, Memari HR. Production and characterization of anti-(mucin MUC1) single-domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi). Biotechnol Appl Biochem. 2007;47(1):11-19. (Pubitemid 46762267)
41. Giritch A, et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci U S A. 2006;103(40):14701-14706. (Pubitemid 44527793)
42. Peeters K, De Wilde C, Depicker A. Highly efficient targeting and accumulation of a F(ab) fragment within the secretory pathway and apoplast of Arabidopsis thaliana. Eur J Biochem. 2001;268(15):4251-4260. (Pubitemid 32862886)
43. Fiedler U, Conrad U. High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds. Biotechnol. 1995;13(10):1090-1093.
44. Tada Y, Utsumi S, Takaiwa F. Foreign gene products can be enhanced by introduction into low storage protein mutants. Plant Biotechnol J. 2003;1(6):411-422.
45. Kirkwood CD. Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J Infect Dis. 2010;202(suppl 1):S43-S48.
46. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science. 1996;272(5258):104-107. (Pubitemid 26110760)
47. Corthesy B, et al. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol. 2006;80(21):10692-10699. (Pubitemid 44628915)
48. Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol. 2002;76(16):8110- 8117. (Pubitemid 34809065)
49. Ruggeri FM, Johansen K, Basile G, Kraehenbuhl JP, Svensson L. Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol. 1998;72(4):2708-2714. (Pubitemid 28175505)
50. Garaicoechea L, et al. Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol. 2008;82(19):9753-9764.
51. Pant N, et al. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis. 2006;194(11):1580-1588. (Pubitemid 44851901)
52. Pant N, et al. Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. Future Microbiol. 2011;6(5):583-593.
53. van der Vaart JM, et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine. 2006;24(19):4130-4137. (Pubitemid 44308223)
54. Pesavento JB, Billingsley AM, Roberts EJ, Ramig RF, Prasad BV. Structures of rotavirus reassortants demonstrate correlation of altered conformation of the VP4 spike and expression of unexpected VP4-associated phenotypes. J Virol. 2003;77(5):3291-3296. (Pubitemid 36228112)
55. Nochi T, et al. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence preexisting intestinal immunity. J Immunol. 2009;183(10):6538-6544.
56. Yuki Y, et al. Induction of toxin-specific neutralizing immunity by molecularly uniform rice-based oral cholera toxin B subunit vaccine without plant-associated sugar modification [published online ahead of print April 22, 2013]. Plant Biotechnol J. doi:10.1111/pbi.12071.
57. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661. (Pubitemid 351348146)
58. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for industry-Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. FDA Web site. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/CM078932.pdf. Updated July 22, 2005. Accessed June 28, 2013.
59. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008;39(2):113-118.
60. Srebalus Barnes CA, Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev. 2007;26(3):370-388. (Pubitemid 46750375)
61. Stucker G, Oshiro LS, Schmidt NJ. Antigenic comparisons of two new rotaviruses from rhesus monkeys. J Clin Microbiol. 1980;11(2):202-203. (Pubitemid 10169145)
62. Takagi H, et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci U S A. 2005;102(48):17525-17530. (Pubitemid 41740899)
63. Oyama M, et al. Temporal perturbation of tyrosine phosphoproteome dynamics reveals the system-wide regulatory networks. Mol Cell Proteomics. 2009;8(2):226-231.
64. Svensson L, Finlay BB, Bass D, von Bonsdorff CH, Greenberg HB. Symmetric infection of rotavirus on polarized human intestinal epithelial (Caco-2) cells. J Virol. 1991;65(8):4190-4197.
65. Ciarlet M, Conner ME, Finegold MJ, Estes MK. Group A rotavirus infection and age-dependent diarrheal disease in rats: a new animal model to study the pathophysiology of rotavirus infection. J Virol. 2002;76(1):41-57. (Pubitemid 33138990)